Travere Therapeutics, Inc.TVTXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR-4.2%
5Y CAGR+8.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-4.2%/yr
Quarterly compound
5Y CAGR
+8.3%/yr
Recent deceleration
Percentile
P77
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.63% |
| Q3 2025 | 13.43% |
| Q2 2025 | 4.64% |
| Q1 2025 | 4.80% |
| Q4 2024 | 5.92% |
| Q3 2024 | 20.55% |
| Q2 2024 | -15.25% |
| Q1 2024 | 21.79% |
| Q4 2023 | -22.22% |
| Q3 2023 | -0.59% |
| Q2 2023 | -5.59% |
| Q1 2023 | 14.82% |
| Q4 2022 | 20.03% |
| Q3 2022 | -1.06% |
| Q2 2022 | 13.23% |
| Q1 2022 | 11.20% |
| Q4 2021 | 16.66% |
| Q3 2021 | 3.15% |
| Q2 2021 | -4.93% |
| Q1 2021 | 2.91% |
| Q4 2020 | 11.85% |
| Q3 2020 | -8.64% |
| Q2 2020 | 5.53% |
| Q1 2020 | 47.06% |
| Q4 2019 | -24.33% |
| Q3 2019 | -23.58% |
| Q2 2019 | 19.29% |
| Q1 2019 | 25.87% |
| Q4 2018 | -0.58% |
| Q3 2018 | 4.01% |
| Q2 2018 | -5.17% |
| Q1 2018 | -2.96% |
| Q4 2017 | 9.75% |
| Q3 2017 | -13.81% |
| Q2 2017 | 24.75% |
| Q1 2017 | -13.18% |
| Q4 2016 | -8.38% |
| Q3 2016 | 25.23% |
| Q2 2016 | 21.33% |
| Q1 2016 | -15.70% |